ClinicalTrials.gg
TerminatedNCT03854032Updated Oct 19, 2026Results posted

Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck

A Phase 2 interventional study of Nivolumab and IDO1 Inhibitor BMS-986205 in Lip, Oral Cavity Squamous Cell Carcinoma and Pharynx, sponsored by Thomas Jefferson University. Terminated at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Thomas Jefferson University · Phase 2, Interventional, and Treatment

How we know · 7 judgments

Why this study was terminated
Study was terminated early due to toxicity concerns by the Sponsor.
Updated Oct 19, 2026Now TerminatedResults posted+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
65
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 46 studies testing nivolumab in Squamous Cell Carcinoma of Head and Neck — 11 open to participants now, 15 under way, 2 of them phase 3. Nivolumab · Squamous Cell Carcinoma of Head and Neck.

Enrollment
15th of 46
65 · median 44
Started
2019
with 9 others
Phase 2
27 of 46
10 open now
Registered
23rd of 46
by date

Among the 46 studies testing nivolumab in Squamous Cell Carcinoma of Head and Neck, this one is the 15th largest by enrollment, is one of 10 that started in 2019, is one of 27 in phase 2, and was the 23rd registered.

Squamous Cell Carcinoma of Head and Neck

2,023 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

11 of the 46 studies testing nivolumab in Squamous Cell Carcinoma of Head and Neck are open now, in 7 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 434 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 310 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing nivolumab in Squamous Cell Carcinoma of Head and Neck, or all of them as a file.
02

Study summary

This phase II trial studies how well nivolumab works, with or without BMS986205, in treating patients with stage II-IV squamous cell cancer of the head and neck. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. BMS986205 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving nivolumab with BMS986205 may work better than nivolumab alone in treating patients with squamous cell cancer of the head and neck.

Read the detailed description

PRIMARY OBJECTIVES:

I. To assess the impact of IDO1 inhibitor BMS-986205 (BMS986205) and nivolumab versus nivolumab alone on tumor radiographic response both at the primary tumor site and in regional lymph nodes by investigator assessment at 5 weeks.

SECONDARY OBJECTIVES:

I. To investigate whether adding the IDO1 - inhibitor, BMS986205, to nivolumab therapy affects intratumoral and systemic anti-tumor immunity.

II. To assess the impact of BMS986205 and nivolumab verses nivolumab alone on pathologic treatment effect bother at the primary and regional lymph nodes.

III. To determine the effect of BMS986205 and nivolumab versus nivolumab alone on immune cell composition within the tumor microenvironment including the presence of effector T cells (Teff), regulatory T cells (Treg), and tumor-associated macrophages (TAM).

IV. To further characterize the effect of BMS986205 when combined with nivolumab on kynurenine production and correlate these levels with effects on immune cell composition and polarization.

V. To review the relationship of p16 status by immunohistochemistry with immune cell polarization, tumor radiographic response, and immune cell composition.

VI. To review the relationship of PD-L1 status by immunohistochemistry with immune cell polarization, tumor radiographic response, and immune cell composition.

VII. To assess the safety and tolerability of BMS986205 and nivolumab. VIII. Evaluate surgical wound healing post treatment.

EXPLORATORY OBJECTIVES:

I. To further characterize the effect of BMS986205 and nivolumab versus nivolumab alone through analysis of T cell repertoire.

II. To assess the interactions between the immune and metabolic microenvironment through analysis of alterations in exosome composition in peripheral blood as it related to immune, cytokine and metabolic alterations before, during and after treatment.

III. To identify risks for poor physical and mental health outcomes; examine bio-behavioral factors associated with cancer treatment outcomes; and evaluate the physical and psychosocial needs of cancer survivors through patient reported outcomes.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Patients receive IDO1 inhibitor BMS-986205 orally (PO) once daily (QD). Beginning week 2, patients also receive nivolumab intravenously (IV) over 30 minutes on day 1. Treatment repeats for up to 5 weeks in the absence of disease progression or unacceptable toxicity. Patients showing a treatment response receive IDO1 inhibitor BMS-986205 PO QD for 4 additional weeks and receive nivolumab IV over 30 minutes on day 1, then undergo surgery at week 10. Those without a treatment response after 5 weeks undergo surgery within 7 days.

ARM II: Patients receive nivolumab IV over 30 minutes on day 1 in the absence of disease progression or unacceptable toxicity. Patients showing treatment response after 4 weeks receive nivolumab IV over 30 minutes on day 1, then undergo surgery at week 9. Those without a treatment response after 4 weeks undergo surgery within 7 days.

After completion of study treatment, patients are followed up periodically for 12 months.

03

Conditions studied

  • Lip
  • Oral Cavity Squamous Cell Carcinoma
  • Pharynx
  • Larynx
  • Squamous Cell Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed head and neck squamous cell carcinoma (HNSC).
  • Any stage 2 or greater HNSCC (American Joint Committee on Cancer [AJCC] 8th edition) of the 1) oral cavity, 2) larynx, 3) hypopharynx, 4) nasal cavity/paranasal sinuses or 5) stage 1 oropharyngeal with lymphadenopathy. Patients with resectable disease that is amenable to surgery are eligible. Patient must have been determined to be candidates for surgical resection by a multi-disciplinary team including a surgeon, a medical oncologist
  • (ECOG) performance status 0-2.
  • White blood cells 2000/ul or more.
  • 1500/ul or more.
  • 100,000/ul or more.
  • 9 g/dl or more.
  • less than or equal to 1.5 x the (except subjects with Gilbert syndrome, who can have total bilirubin \< 3 mg/dl).
  • (AST) and alanine aminotransferase (ALT) less than or equal to 3 x the upper limit of normal.
  • (GFR) greater than or equal to 40 ml/min using the formula or serum creatinine less than or equal to 1.5 x ULN.
  • Women of child bearing potential () should have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [HCG]) within 21 days of study enrollment.
  • WOCBP must agree to follow instructions for method(s) of for the duration of treatment with study treatment(s) plus 5 months post-treatment completion.
  • Males who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with study treatment(s) plus 7 months post-treatment completion. In addition, male participants must be willing to refrain from sperm donation during this time.
  • Males who are sexually active with WOCBP must agree to use a condom during any sexual activity for the duration of treatment with study treatment plus 7 months after the last dose of the study treatment (i.e., 90 days [duration of sperm turnover] plus the time required for nivolumab to undergo approximately 5 half-lives). This criterion applies to azoospermic males as well. In addition, male participants must be willing to refrain from sperm donation during this time.

    • Male mandatory condom use is regardless of whether the participant has undergone a successful vasectomy or if the female partner is pregnant.
    • Investigators shall counsel WOCBP, and male participants who are sexually active with WOCBP, on the importance of pregnancy prevention and the implications of an unexpected pregnancy. Investigators shall advise on the use of highly effective methods of contraception, which have a failure rate of \< 1% when used consistently and correctly. Hormonal contraceptives are prohibited methods of contraception for participants receiving BMS-986205 this study who are WOCBP.
  • All subjects must be able to comprehend and sign a written document.

Exclusion criteria

Exclusion Criteria:

  • Patients with nasopharyngeal carcinoma, salivary gland or skin primaries.
  • Patients with recurrent head and neck cancer treated previously with chemotherapy, radiation or immunotherapy.
  • Any history of a severe reaction to any monoclonal antibody.
  • Any history of allergy to the study drug components.
  • Participants with a personal or family (i.e., in a first-degree relative) history or presence of cytochrome b5 reductase deficiency (previously called methemoglobin reductase deficiency) or other diseases that puts them at risk of methemoglobinemia. All participants will be screened for methemoglobin levels prior to randomization.
  • Participants with a history of G6PD deficiency or other congenital or hemolytic disorders. All participants will be screened for G6PD deficiency prior to randomization.
  • Participants with history of serotonin syndrome.
  • Participants with active interstitial lung disease (ILD)/pneumonitis or history of ILD/ pneumonitis requiring .
  • Prior treatment with BMS-986205 or any other IDO1 inhibitors.
  • Quantitative or qualitative G6PD assay results suggesting underlying G6PD deficiency.
  • Blood methemoglobin > (ULN), assessed in an arterial or venous blood sample or by co-oximetry.
  • History or presence of hypersensitivity or idiosyncratic reaction to methylene blue.
  • History of allergy or hypersensitivity to any study treatment components, specifically to that of BMS-986205.
  • Any concurrent ; exceptions include- basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer or in situ cervical cancer that has undergone potentially curative therapy. Patients with a history of other prior malignancy must have been treated with curative intent and must have remained disease-free for 2 years post-diagnosis.
  • Any diagnosis of immunodeficiency or receiving systemic steroid therapy (> 10 mg daily prednisone equivalents) or any other form of therapy within 14 days of initiation of therapy.
  • Patients that have an active autoimmune disease requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids (> 10 mg daily prednisone equivalents) or immunosuppressive agents. Subjects with vitiligo, type I diabetes mellitus, or resolved childhood asthma/atopy would be an exception to this rule. Subjects that require intermittent use of bronchodilators or local steroid injections would not be excluded from the study. Subjects with hypothyroidism stable on hormone replacement or Sjogren's syndrome will not be excluded from the study.
  • Patients must not be receiving any other agents.
  • Patients with uncontrolled intercurrent illnesses including, but not limited to an active infection requiring systemic therapy or a known psychiatric or substance abuse disorder(s) that would interfere with cooperation with the requirements of the trial.
  • Patients must not be pregnant or breastfeeding.
  • Patients with a known infection (HIV 1/2 antibodies) or acquired immunodeficiency syndrome (HIV/AIDS), active (e.g., hepatitis B surface antigen [HBsAg] reactive) or (e.g., hepatitis C virus [HCV] ribonucleic acid [RNA] [qualitative] is detected).
  • Patients with any evidence of current interstitial lung disease (ILD) or pneumonitis.
  • Patients with prior history of ILD or non-infectious pneumonitis that required steroids.
  • Patients who have received a within 30 days of the planned start of study therapy.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
65 participants (actual)

Study arms

  • Experimental
    Arm A: BMS986205 + Nivolumab

    Patients receive IDO1 inhibitor BMS-986205 PO QD. Beginning week 2, patients also receive nivolumab IV over 30 minutes on day 1. Treatment repeats for up to 5 weeks in the absence of disease progression or unacceptable toxicity. Patients showing a treatment response receive IDO1 inhibitor BMS-986205 PO QD for 4 additional weeks and receive nivolumab IV over 30 minutes on day 1, then undergo surgery at week 10. Those without a treatment response after 5 weeks undergo surgery within 7 days. Nivolumab is administered as a 480mg intravenous (IV) infusion once every 4 weeks. BMS986205 is administered orally at a dose of 100 mg once daily.

    Biological: Nivolumab · Biological: IDO1 Inhibitor BMS-986205 · Procedure: Therapeutic Conventional Surgery · Other: Questionnaire Administration

  • Experimental
    Arm B: Group I - Nivolumab Only

    Patients receive nivolumab IV over 30 minutes on day 1 in the absence of disease progression or unacceptable toxicity. Patients showing treatment response after 4 weeks receive nivolumab IV over 30 minutes on day 1, then undergo surgery at week 9. Those without a treatment response after 4 weeks undergo surgery within 7 days. Nivolumab is administered as a 480mg intravenous (IV) infusion once every 4 weeks.

    Biological: Nivolumab · Procedure: Therapeutic Conventional Surgery · Other: Questionnaire Administration

  • No intervention
    Arm C: Group II - Nivolumab Only

    Data from Contemporaneous Study 10237 (NCT03238365) participants who received Nivolumab alone prior to surgery is used as a historical controls under the current window of treatment (WOT), to bolster the control group. Nivolumab was administered as a 240mg intravenous (IV) infusion every 2 weeks for 2 doses over a 4-week treatment period prior to surgical resection.

Interventions

  • BiologicalNivolumab

    Given IV

    Also known as: 946414-94-4, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo

  • BiologicalLinrodostatStudies of LinrodostatLinrodostat pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Given PO

    Also known as: (R)-N-(4-chlorophenyl)-2-((1S,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propenamide, BMS 986205, BMS-986205, BMS986205, IDO-1 Inhibitor BMS-986205, Indoleamine-pyrrole 2,3-Dioxygenase Inhibitor BMS-986205, ONO-7701

  • ProcedureTherapeutic Conventional Surgery

    Undergo Surgery

  • OtherQuestionnaire Administration

    Ancillary studies

06

What researchers measure

Primary outcomes

  1. Objective Response

    Radiographic response was assessed at the primary site and involved lymph nodes. Participants with ≥10% volumetric reduction at either site and no progression received a second treatment cycle before surgery, while those with stable disease or progression proceeded to surgery at the 5-week evaluation. The study hypothesized that adding an IDO inhibitor to PD-1 blockade would improve radiographic response. The primary endpoint was the proportion of participants eligible for a second cycle. The 10% cutoff was based on prior publications showing that volumetric analysis is more sensitive than single-axis RECIST v1.1 and allows minor immune-related increases (0-9%) while defining \>10% growth as progression.

    Time frame: At 5 weeks

Secondary outcomes

  1. Objective Pathologic Response at Time of Surgery

    Pathologic specimens were independently graded by two pathologists as outlined in our previous publication (2). The entire mass or surgical specimen (in the event of a partial/ complete response) was sectioned to calculate the pTR. Criteria for response included evidence of macrophage reaction, multinucleated giant cells and granulomas, fibrosis adjacent to residual tumor nests. In complete responders where no more viable tumor was identified, alteration of the normal tissue architecture by fibrosis and macrophage reaction was used to identify areas of previously viable malignancy. Tumors with pTR of ≥20% were defined as responders (R), while those with pTR \<20% were defined as minimal or non-responders (NR) at the primary site and Lymph Nodes (LNs).

    Time frame: At time of surgery

  2. Change in Immune Cell Polarization (Th1/Th2; M1/M2) in Peripheral Blood and Tumor Specimens

    Will be analyzed and compared using multiplex cytokine analysis collected before and after exposure to nivolumab +/- IDO1 inhibitor BMS-986205 (BMS986205). If there is at least one significant difference between groups among the primary outcomes, the two randomization arms will be compared with respect to each secondary outcome using two-sample t-tests. P-values for comparisons of changes in secondary outcomes will be adjusted using the method of Benjamini and Hochberg to control the FDR among the secondary outcomes at 5%.

    Time frame: Baseline up to 12 months

  3. Change in Inflammatory Markers

    These include soluble (s)CD40 ligand (L), EGF, eotaxin, FGF-2, Flt-3 ligand, fractalkine, granulocyte colony-stimulating factor (G-CSF), granulocyte colony-macrophage (GM)-CSF, GRO, IFN-alpha2, IL-1alpha, IL-1beta, IL-1ra, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-12 (p40), IL-13, IL-15, IL-17A, IP-10, MCP-1, MCP-3, MDC (CCL22), MIP-1alpha, MIP-1beta, PDGF-AA, PDGF-AB/BB, RANTES, TGF-alpha, TNF-alpha, VEGF. If there is at least one significant difference between groups among the primary outcomes, the two randomization arms will be compared with respect to each secondary outcome using two-sample t-tests. P-values for comparisons of changes in secondary outcomes will be adjusted using the method of Benjamini and Hochberg to control the FDR among the secondary outcomes at 5%

    Time frame: Baseline up to 12 months

  4. Change in Prevalence of Intratumoral Immune Cell Populations (Effector T Cells [Teff], Regulatory T Cells [Treg], and Tumor-associated Macrophages [TAM] in Patients Treated With Nivolumab and BMS986205 as Compared to Patients Treated With Nivolumab Alone

    Assessed by immunohistochemistry (IHC). If there is at least one significant difference between groups among the primary outcomes, the two randomization arms will be compared with respect to each secondary outcome using two-sample t-tests. P-values for comparisons of changes in secondary outcomes will be adjusted using the method of Benjamini and Hochberg to control the FDR among the secondary outcomes at 5%.

    Time frame: Baseline up to 12 months

  5. Localization of Immune Cells Within the Tumor

    Will be analyzed using confocal microscopy.

    Time frame: Up to 12 months

  6. Multiplex Colocalization of Resident Immune Cells

    Will utilize 5-6 markers per section.

    Time frame: Up to 12 months

  7. Ratio of Tryptophan to Kynurenine

    Tryptophan and kynurenine concentrations were measured in plasma samples using validated assays. The outcome is expressed as the ratio of tryptophan to kynurenine, a marker of IDO1 activity. Results are reported as median values with full range (minimum to maximum) across participants

    Time frame: Up to 12 months

  8. Intratumoral Immune Cell Populations, Immune Polarization Data, Exosome Composition, and Exosome Function in Human Papilloma Virus (HPV) + and HPV- Tumors

    Baseline IHC staining for P16 will be performed as a surrogate for HPV status. If there is at least one significant difference between groups among the primary outcomes, the two randomization arms will be compared with respect to each secondary outcome using two-sample t-tests. P-values for comparisons of changes in secondary outcomes will be adjusted using the method of Benjamini and Hochberg to control the FDR among the secondary outcomes at 5%.

    Time frame: Up to 12 months

  9. Intratumoral Immune Cell Populations, Immune Polarization Data, Exosome Composition, and Exosome Function Relative to PD-L1 Expression Levels

    Assessed by IHC. If there is at least one significant difference between groups among the primary outcomes, the two randomization arms will be compared with respect to each secondary outcome using two-sample t-tests. P-values for comparisons of changes in secondary outcomes will be adjusted using the method of Benjamini and Hochberg to control the FDR among the secondary outcomes at 5%.

    Time frame: Up to 12 months

  10. Number of Immune Related Adverse Events

    Number of immune related adverse events. Adverse Events will be graded by Common Terminology Criteria for Adverse Events version 5.0.

    Time frame: Up to 100 days

Other outcomes

  1. Intratumoral T-cell Receptor (TCR) Repertoire and Diversity

    Assesses with next generation sequencing.

    Time frame: Up to 12 months

  2. Change in Exosome Abundance and Composition in the Peripheral Blood of Patients Both Before and After Exposure to Both Nivolumab and BMS986205 and Nivolumab Alone

    Will be compared between treatment arms using two-sample t-tests.

    Time frame: Baseline up to 12 months

  3. Number of Participants With Wound Dehiscence

    Number of Participants with wound dehiscence, postop wound infection (requiring antibiotics), and fistula formation

    Time frame: Up to 12 months

  4. Changes in Tumor Volume and Rates of Radiographic Response

    Will be summarized by treatment arm and compared using two-sample t-tests or Fisher's exact test, as appropriate.

    Time frame: Baseline up to 12 months

  5. Patient-reported Outcomes

    Data will be collected and correlated to both immune cell composition and polarization and tumor radiographic response using scores from Patient Health Questionnaire (PHQ)2/9, Functional Assessment of Cancer Therapy- General (FACT-G), and FACT-head and neck (HN). Will conduct descriptive statistics and will summarize variable of interest using standard statistics such as frequency tables, means, and standard deviations. All measures will be evaluated for reliability and factor analyses will be conducted.

    Time frame: Up to 12 months

07

Results

Posted Oct 19, 2026

Participant flow

Participant flow — Overall Study
MilestoneArm A: BMS986205 + NivolumabArm B: Group I - Nivolumab OnlyArm C: Group II - Nivolumab Only
Started311123
Completed271119
Not completed404
Withdrew: Withdrawal by subject403
Withdrew: Death001

Outcome measures

PrimaryObjective Response

Radiographic response was assessed at the primary site and involved lymph nodes. Participants with ≥10% volumetric reduction at either site and no progression received a second treatment cycle before surgery, while those with stable disease or progression proceeded to surgery at the 5-week evaluation. The study hypothesized that adding an IDO inhibitor to PD-1 blockade would improve radiographic response. The primary endpoint was the proportion of participants eligible for a second cycle. The 10% cutoff was based on prior publications showing that volumetric analysis is more sensitive than single-axis RECIST v1.1 and allows minor immune-related increases (0-9%) while defining \>10% growth as progression.

Time frame:
At 5 weeks
Reported as:
Count of participants · Participants
Objective Response
ParticipantsArm A: BMS986205 + NivolumabArm B: Group I - Nivolumab OnlyArm C: Group II - Nivolumab Only
Radiographic Responders13410
Radiographic Non-Responders1479
SecondaryObjective Pathologic Response at Time of Surgery

Pathologic specimens were independently graded by two pathologists as outlined in our previous publication (2). The entire mass or surgical specimen (in the event of a partial/ complete response) was sectioned to calculate the pTR. Criteria for response included evidence of macrophage reaction, multinucleated giant cells and granulomas, fibrosis adjacent to residual tumor nests. In complete responders where no more viable tumor was identified, alteration of the normal tissue architecture by fibrosis and macrophage reaction was used to identify areas of previously viable malignancy. Tumors with pTR of ≥20% were defined as responders (R), while those with pTR \<20% were defined as minimal or non-responders (NR) at the primary site and Lymph Nodes (LNs).

Time frame:
At time of surgery
Reported as:
Count of participants · Participants
Objective Pathologic Response at Time of Surgery
ParticipantsArm A: BMS986205 + NivolumabArm B: Group I - Nivolumab OnlyArm C: Group II - Nivolumab Only
Responders166—
Non-Responders115—
SecondaryChange in Immune Cell Polarization (Th1/Th2; M1/M2) in Peripheral Blood and Tumor Specimens

Will be analyzed and compared using multiplex cytokine analysis collected before and after exposure to nivolumab +/- IDO1 inhibitor BMS-986205 (BMS986205). If there is at least one significant difference between groups among the primary outcomes, the two randomization arms will be compared with respect to each secondary outcome using two-sample t-tests. P-values for comparisons of changes in secondary outcomes will be adjusted using the method of Benjamini and Hochberg to control the FDR among the secondary outcomes at 5%.

Time frame:
Baseline up to 12 months

No measurements were reported for this outcome.

SecondaryChange in Inflammatory Markers

These include soluble (s)CD40 ligand (L), EGF, eotaxin, FGF-2, Flt-3 ligand, fractalkine, granulocyte colony-stimulating factor (G-CSF), granulocyte colony-macrophage (GM)-CSF, GRO, IFN-alpha2, IL-1alpha, IL-1beta, IL-1ra, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-12 (p40), IL-13, IL-15, IL-17A, IP-10, MCP-1, MCP-3, MDC (CCL22), MIP-1alpha, MIP-1beta, PDGF-AA, PDGF-AB/BB, RANTES, TGF-alpha, TNF-alpha, VEGF. If there is at least one significant difference between groups among the primary outcomes, the two randomization arms will be compared with respect to each secondary outcome using two-sample t-tests. P-values for comparisons of changes in secondary outcomes will be adjusted using the method of Benjamini and Hochberg to control the FDR among the secondary outcomes at 5%

Time frame:
Baseline up to 12 months

No measurements were reported for this outcome.

SecondaryChange in Prevalence of Intratumoral Immune Cell Populations (Effector T Cells [Teff], Regulatory T Cells [Treg], and Tumor-associated Macrophages [TAM] in Patients Treated With Nivolumab and BMS986205 as Compared to Patients Treated With Nivolumab Alone

Assessed by immunohistochemistry (IHC). If there is at least one significant difference between groups among the primary outcomes, the two randomization arms will be compared with respect to each secondary outcome using two-sample t-tests. P-values for comparisons of changes in secondary outcomes will be adjusted using the method of Benjamini and Hochberg to control the FDR among the secondary outcomes at 5%.

Time frame:
Baseline up to 12 months

No measurements were reported for this outcome.

SecondaryLocalization of Immune Cells Within the Tumor

Will be analyzed using confocal microscopy.

Time frame:
Up to 12 months

No measurements were reported for this outcome.

SecondaryMultiplex Colocalization of Resident Immune Cells

Will utilize 5-6 markers per section.

Time frame:
Up to 12 months

No measurements were reported for this outcome.

SecondaryRatio of Tryptophan to Kynurenine

Tryptophan and kynurenine concentrations were measured in plasma samples using validated assays. The outcome is expressed as the ratio of tryptophan to kynurenine, a marker of IDO1 activity. Results are reported as median values with full range (minimum to maximum) across participants

Time frame:
Up to 12 months
Reported as:
Median · Ratio of Tryptophan to Kynurenine
Ratio of Tryptophan to Kynurenine
Ratio of Tryptophan to KynurenineArm A: BMS986205 + NivolumabArm B: Group I - Nivolumab OnlyArm C: Group II - Nivolumab Only
Pre-Kynurenine Responders0.5 (-1 to 1.8)-0.1 (-1.4 to 0.65)—
Pre-Kynurenine Non-Responders-0.2 (-1.3 to 1)0 (-1.2 to 0.8)—
SecondaryIntratumoral Immune Cell Populations, Immune Polarization Data, Exosome Composition, and Exosome Function in Human Papilloma Virus (HPV) + and HPV- Tumors

Baseline IHC staining for P16 will be performed as a surrogate for HPV status. If there is at least one significant difference between groups among the primary outcomes, the two randomization arms will be compared with respect to each secondary outcome using two-sample t-tests. P-values for comparisons of changes in secondary outcomes will be adjusted using the method of Benjamini and Hochberg to control the FDR among the secondary outcomes at 5%.

Time frame:
Up to 12 months

No measurements were reported for this outcome.

SecondaryIntratumoral Immune Cell Populations, Immune Polarization Data, Exosome Composition, and Exosome Function Relative to PD-L1 Expression Levels

Assessed by IHC. If there is at least one significant difference between groups among the primary outcomes, the two randomization arms will be compared with respect to each secondary outcome using two-sample t-tests. P-values for comparisons of changes in secondary outcomes will be adjusted using the method of Benjamini and Hochberg to control the FDR among the secondary outcomes at 5%.

Time frame:
Up to 12 months

No measurements were reported for this outcome.

SecondaryNumber of Immune Related Adverse Events

Number of immune related adverse events. Adverse Events will be graded by Common Terminology Criteria for Adverse Events version 5.0.

Time frame:
Up to 100 days
Reported as:
Number · Adverse Events
Number of Immune Related Adverse Events
Adverse EventsArm A: BMS986205 + NivolumabArm B: Group I - Nivolumab OnlyArm C: Group II - Nivolumab Only
Number of Immune Related Adverse Events14215
Other pre-specifiedIntratumoral T-cell Receptor (TCR) Repertoire and Diversity

Assesses with next generation sequencing.

Time frame:
Up to 12 months

No measurements were reported for this outcome.

Other pre-specifiedChange in Exosome Abundance and Composition in the Peripheral Blood of Patients Both Before and After Exposure to Both Nivolumab and BMS986205 and Nivolumab Alone

Will be compared between treatment arms using two-sample t-tests.

Time frame:
Baseline up to 12 months

No measurements were reported for this outcome.

Other pre-specifiedNumber of Participants With Wound Dehiscence

Number of Participants with wound dehiscence, postop wound infection (requiring antibiotics), and fistula formation

Time frame:
Up to 12 months
Reported as:
Count of participants · Participants
Number of Participants With Wound Dehiscence
ParticipantsArm A: BMS986205 + NivolumabArm B: Group I - Nivolumab OnlyArm C: Group II - Nivolumab Only
Number of Participants With Wound Dehiscence002
Other pre-specifiedChanges in Tumor Volume and Rates of Radiographic Response

Will be summarized by treatment arm and compared using two-sample t-tests or Fisher's exact test, as appropriate.

Time frame:
Baseline up to 12 months

No measurements were reported for this outcome.

Other pre-specifiedPatient-reported Outcomes

Data will be collected and correlated to both immune cell composition and polarization and tumor radiographic response using scores from Patient Health Questionnaire (PHQ)2/9, Functional Assessment of Cancer Therapy- General (FACT-G), and FACT-head and neck (HN). Will conduct descriptive statistics and will summarize variable of interest using standard statistics such as frequency tables, means, and standard deviations. All measures will be evaluated for reliability and factor analyses will be conducted.

Time frame:
Up to 12 months

No measurements were reported for this outcome.

Adverse events

Collected over Adverse event reporting will begin after study treatment, unless the AE/SAE is caused by a study specific screening procedure, and continue until 100 days (for non-serious AEs) or 100 days (for SAEs) after the last day of study participation. Up to 14 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A: BMS986205 + Nivolumab0/31 (0%)6/31 (19.4%)30/31 (96.8%)
Arm B: Group I - Nivolumab Only0/11 (0%)1/11 (9.1%)11/11 (100%)
Arm C: Group II - Nivolumab Only1/23 (4.3%)1/23 (4.3%)13/23 (56.5%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventArm A: BMS986205 + NivolumabArm B: Group I - Nivolumab OnlyArm C: Group II - Nivolumab Only
Febrile neutropeniaBlood and lymphatic system disorders1/311/110/23
DyspneaRespiratory, thoracic and mediastinal disorders2/310/110/23
Endocrine disorders - Other, specifyEndocrine disorders0/310/111/23
DeathGeneral disorders0/310/111/23
AspirationRespiratory, thoracic and mediastinal disorders1/310/110/23
ConfusionPsychiatric disorders1/310/110/23
Respiratory, thoracic and mediastinal disorders - Other, specifyRespiratory, thoracic and mediastinal disorders1/310/110/23
Investigations - Other, specifyInvestigations1/310/110/23
HematomaVascular disorders1/310/110/23
HypokalemiaMetabolism and nutrition disorders1/310/110/23
Most frequent other events
Showing 10 of 174
Most frequent other events
EventArm A: BMS986205 + NivolumabArm B: Group I - Nivolumab OnlyArm C: Group II - Nivolumab Only
DysphagiaGastrointestinal disorders21/318/110/23
FatigueGeneral disorders16/317/110/23
Pain - OralGastrointestinal disorders9/315/110/23
Sore ThroatRespiratory, thoracic and mediastinal disorders13/315/110/23
Weight LossInvestigations9/315/110/23
RashSkin and subcutaneous tissue disorders1/311/119/23
Dry MouthGastrointestinal disorders7/314/110/23
HoarsenessRespiratory, thoracic and mediastinal disorders11/312/110/23
NauseaGastrointestinal disorders10/310/110/23
ConstipationGastrointestinal disorders9/312/110/23

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Arm A: BMS986205 + NivolumabArm B: Group I - Nivolumab OnlyArm C: Group II - Nivolumab OnlyTotal
<=18 years0000
Between 18 and 65 years1961237
>=65 years125724
Sex: Female, Male
Sex: Female, Male(Participants)Arm A: BMS986205 + NivolumabArm B: Group I - Nivolumab OnlyArm C: Group II - Nivolumab OnlyTotal
Female83112
Male2381849
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm A: BMS986205 + NivolumabArm B: Group I - Nivolumab OnlyArm C: Group II - Nivolumab OnlyTotal
Hispanic or Latino1012
Not Hispanic or Latino29111858
Unknown or Not Reported1001
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm A: BMS986205 + NivolumabArm B: Group I - Nivolumab OnlyArm C: Group II - Nivolumab OnlyTotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American2024
White28111655
More than one race0000
Unknown or Not Reported1012
Region of Enrollment
Region of Enrollment(participants)Arm A: BMS986205 + NivolumabArm B: Group I - Nivolumab OnlyArm C: Group II - Nivolumab OnlyTotal
United States31111961
08

Study locations

2 sites
  • Ohio State University
    Columbus, Ohio 43210, United States
  • Sidney Kimmel Cancer Center at Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Apr 2019 to primary completion in Feb 2022, 34 months.

Results were first posted in Oct 2026, 4 years 8 months after primary completion.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 19, 2026: primary completion Dec 2025 → Feb 2022 and completion Dec 2025 → Mar 2023.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2019
First posted
Feb 26, 2019
StartActual
Apr 9, 2019
Primary completionActual
Feb 10, 2022was Dec 2025
CompletionActual
Mar 14, 2023was Dec 2025
Results first posted
Oct 19, 2026
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Terminated Study was terminated early due to toxicity concerns by the Sponsor.
changed Oct 19, 2026
Results
Results posted
posted Oct 19, 2026
Primary completion
Dec 31, 2025→Feb 10, 2022 (actual)
Oct 19, 2026
Study completion
Dec 31, 2025→Mar 14, 2023 (actual)
Oct 19, 2026
Enrollment
45→65
Oct 19, 2026
Interventions
Arms added: Arm A: BMS986205 + Nivolumab·Arm B: Group I - Nivolumab Only·Arm C: Group II - Nivolumab Only; arms removed: Arm I (BMS986205, nivolumab)·Arm II (nivolumab)
Oct 19, 2026
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionObjective Response: how it is measured was reworded
Oct 19, 2026
Documents
Secondary outcomes
15 edited
What changed in the outcomes
  • EditedObjective pathologic responsePathologic Response at timeTime of surgerySurgeryTime frame: At time of surgery
  • EditedChange in immune cell polarizationImmune Cell Polarization (Th1/Th2; M1/M2) in peripheral bloodPeripheral Blood and tumor specimensTumor SpecimensTime frame: Baseline up to 12 months
  • EditedChange in inflammatory markersInflammatory MarkersTime frame: Baseline up to 12 months
  • EditedChange in prevalencePrevalence of intratumoral immune cell populationsIntratumoral Immune Cell Populations (effectorEffector T cellsCells [Teff], regulatoryRegulatory T cellsCells [Treg], and tumorTumor-associated macrophagesMacrophages [TAM] in patients treated withPatients Treated With Nivolumab and BMS986205 as comparedCompared to patients treated withPatients Treated With Nivolumab aloneAloneTime frame: Baseline up to 12 months
  • EditedLocalization of immune cells withinImmune Cells Within the tumorTumorTime frame: Up to 12 months
  • EditedMultiplex colocalizationColocalization of resident immune cellsResident Immune CellsTime frame: Up to 12 months
  • EditedIntratumoral immune cell populationsImmune Cell Populations, immune polarization dataImmune Polarization Data, exosome compositionExosome Composition, and exosome functionExosome Function in human papilloma virusHuman Papilloma Virus (HPV) + and HPV- tumorsTumorsTime frame: Up to 12 months
  • EditedIntratumoral immune cell populationsImmune Cell Populations, immune polarization dataImmune Polarization Data, exosome compositionExosome Composition, and exosome function relativeExosome Function Relative to PD-L1 expression levelsExpression LevelsTime frame: Up to 12 months
  • EditedIncidenceNumber of adverse eventsImmune Related Adverse EventsTime frame: Up to 100 days
  • ChangedBefore Kynurenine levels (blood and tumor)Now Ratio of Tryptophan to KynurenineTime frame: Up to 12 months
  • Editedother outcomeIntratumoral T-cell receptorReceptor (TCR) repertoireRepertoire and diversityDiversityTime frame: Up to 12 months
  • Editedother outcomeChange in exosome abundanceExosome Abundance and compositionComposition in the peripheral bloodPeripheral Blood of patients both beforePatients Both Before and after exposureAfter Exposure to both nivolumabBoth Nivolumab and BMS986205 and nivolumab aloneNivolumab AloneTime frame: Baseline up to 12 months
  • Editedother outcomeChanges in tumor volumeTumor Volume and ratesRates of radiographic responseRadiographic ResponseTime frame: Baseline up to 12 months
  • Editedother outcomePatient-reported outcomesOutcomesTime frame: Up to 12 months
  • Changedother outcomeBefore Rates of wound dehiscence, postop wound infection (requiring antibiotics), and fistula formationNow Number of Participants With Wound DehiscenceTime frame: Up to 12 months
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Active, not recruiting→Terminated
    Why stopped Study was terminated early due to toxicity concerns by the Sponsor.
    Results posted
    Primary completion Dec 31, 2025→Feb 10, 2022 (now actual)
    Study completion Dec 31, 2025→Mar 14, 2023 (now actual)
    Enrollment 45→65
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionObjective Response: how it is measured was reworded
    Secondary outcomes 15 edited
    What changed in the outcomes
    • EditedObjective pathologic responsePathologic Response at timeTime of surgerySurgeryTime frame: At time of surgery
    • EditedChange in immune cell polarizationImmune Cell Polarization (Th1/Th2; M1/M2) in peripheral bloodPeripheral Blood and tumor specimensTumor SpecimensTime frame: Baseline up to 12 months
    • EditedChange in inflammatory markersInflammatory MarkersTime frame: Baseline up to 12 months
    • EditedChange in prevalencePrevalence of intratumoral immune cell populationsIntratumoral Immune Cell Populations (effectorEffector T cellsCells [Teff], regulatoryRegulatory T cellsCells [Treg], and tumorTumor-associated macrophagesMacrophages [TAM] in patients treated withPatients Treated With Nivolumab and BMS986205 as comparedCompared to patients treated withPatients Treated With Nivolumab aloneAloneTime frame: Baseline up to 12 months
    • EditedLocalization of immune cells withinImmune Cells Within the tumorTumorTime frame: Up to 12 months
    • EditedMultiplex colocalizationColocalization of resident immune cellsResident Immune CellsTime frame: Up to 12 months
    • EditedIntratumoral immune cell populationsImmune Cell Populations, immune polarization dataImmune Polarization Data, exosome compositionExosome Composition, and exosome functionExosome Function in human papilloma virusHuman Papilloma Virus (HPV) + and HPV- tumorsTumorsTime frame: Up to 12 months
    • EditedIntratumoral immune cell populationsImmune Cell Populations, immune polarization dataImmune Polarization Data, exosome compositionExosome Composition, and exosome function relativeExosome Function Relative to PD-L1 expression levelsExpression LevelsTime frame: Up to 12 months
    • EditedIncidenceNumber of adverse eventsImmune Related Adverse EventsTime frame: Up to 100 days
    • ChangedBefore Kynurenine levels (blood and tumor)Now Ratio of Tryptophan to KynurenineTime frame: Up to 12 months
    • Editedother outcomeIntratumoral T-cell receptorReceptor (TCR) repertoireRepertoire and diversityDiversityTime frame: Up to 12 months
    • Editedother outcomeChange in exosome abundanceExosome Abundance and compositionComposition in the peripheral bloodPeripheral Blood of patients both beforePatients Both Before and after exposureAfter Exposure to both nivolumabBoth Nivolumab and BMS986205 and nivolumab aloneNivolumab AloneTime frame: Baseline up to 12 months
    • Editedother outcomeChanges in tumor volumeTumor Volume and ratesRates of radiographic responseRadiographic ResponseTime frame: Baseline up to 12 months
    • Editedother outcomePatient-reported outcomesOutcomesTime frame: Up to 12 months
    • Changedother outcomeBefore Rates of wound dehiscence, postop wound infection (requiring antibiotics), and fistula formationNow Number of Participants With Wound DehiscenceTime frame: Up to 12 months
    Interventions Arms added: Arm A: BMS986205 + Nivolumab·Arm B: Group I - Nivolumab Only·Arm C: Group II - Nivolumab Only; arms removed: Arm I (BMS986205, nivolumab)·Arm II (nivolumab)
    + 5 other changes: identifiers, verification date, contact details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03854032
Responsible party
Sponsor
First posted
Feb 26, 2019
Start date
Apr 9, 2019
Primary completion
Feb 10, 2022
Completion
Mar 14, 2023
Results posted
Oct 19, 2026
Last update
Oct 19, 2026

Study contacts

Adam Luginbuhl, MD
principal investigator · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nivolumab · Linrodostat

Start the discussion